Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

Lilly says Zepbound cut health costs in older adults (LLY:NYSE)

Eli Lilly (LLY) says long-term use of its blockbuster weight loss therapy Zepbound was linked to lower healthcare costs over time in older adults. Read more here.

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from a real-world study of adults over 55 with overweight or obesity, which found...

Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial

A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.

Study finds Zepbound cuts healthcare costs for older adults with obesity

INDIANAPOLIS – Eli Lilly and Co. has announced results from a real-world study of adults over 55 with overweight or obesity, which found that staying on Zepbound (tirzepatide) for weight management lowered healthcare costs over time relative to similar untreated adults, driven in part by fewer hospital admissions and emergency department visits. For adults over the age of 55, including patients in Medicare's GLP-1 Bridge program, these lower cos…